In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
We must try to make the health care system more accessible for people with disabilities
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
A post approval change order is often necessary, but innovators should plan and prepare for this pre-approval. Planning alongside outsourcing partners will help ensure that only a small-scale study is needed—not a new full clinical study
The pharma companies will bring quality products at competitive prices to consumers in Oman and help bring down the cost of healthcare
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
